Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3
DEPT OF DEFENSE
At a glance
This is a government contract opportunity posted by DEPT OF DEFENSE in the research and development in biotechnology (except nanobiotechnology) category. The deadline is July 29, 2026, 27 days from now.
Classification and identifiers
- Industry (NAICS)
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- Product or service (PSC)
- National Defense R&D Services; Department of Defense - Military; Applied Research (AC12)
- Solicitation number
- DARPA-PA-26-09
- Contracting office
- DEF ADVANCED RESEARCH PROJECTS AGCY
About this opportunity
Please note that this announcement specifically solicits proposals only for Task Area 3 (TA-3) of the RAPIID program. Primary challenges with translating technological advancements from the laboratory to real-world usage include a lack of investment to ensure manufacturing scalability, and usability, as well as clinical, regulatory, and commercialization preparedness. Previous investments by DARPA to address potential blood shortages in austere, pre-hospital settings (i.e., the Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP) program) have derisked scalable, shelf-stable components that would provide the resuscitative functions of whole blood (i.e., oxygen delivery, hemostasis, and volume expansion) when used together. However, bringing those component...